Marksans Pharma Limited has informed the Exchange regarding a press release dated November 20, 2025, titled "Marksans Pharma Limited's wholly owned subsidiary Relonchem Limited receives Marketing Authorisation for its product Cetirizine Dihydrochloride 1 mg/ml oral solution".
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Marksans Pharma's wholly owned UK-based subsidiary, Relonchem Limited, has received Marketing Authorisation for Cetirizine Dihydrochloride 1 mg/ml oral solution. Cetirizine is a widely used over-the-counter antihistamine for allergy relief. This regulatory approval allows Relonchem to market and sell the product in the relevant market. The move expands the subsidiary's product portfolio in the generic/allergy therapeutics space. No financial figures or revenue projections were disclosed in the announcement.
This is a positive but routine regulatory milestone that strengthens Relonchem's product pipeline and could add to future revenue, though it is unlikely to cause an immediate significant movement in Marksans Pharma's stock price given the small scale of a single product authorisation.